CURX (Curanex Pharmaceuticals) Beginning Cash Position: $4.97 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CURX Curanex Pharmaceuticals Inc CURX
12 GF Score
Price $0.21
View Full Analysis

What is Curanex Pharmaceuticals Beginning Cash Position?

Curanex Pharmaceuticals CURX +7.43% 12 Beginning Cash Position is $4.97 Mil as of Mar. 2026. GuruFocus rates CURX with a GF Score™ of 12/100.

Curanex Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2026 was $4.97 Mil.

Curanex Pharmaceuticals's quarterly Beginning Cash Position increased from Sep. 2025 ($0.11 Mil) to Dec. 2025 ($5.83 Mil) but then declined from Dec. 2025 ($5.83 Mil) to Mar. 2026 ($4.97 Mil).

Curanex Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.08 Mil) and increased from Dec. 2024 ($0.08 Mil) to Dec. 2025 ($0.15 Mil).

Curanex Pharmaceuticals Beginning Cash Position Related Terms

Curanex Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Curanex Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curanex Pharmaceuticals Beginning Cash Position Chart

Curanex Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
0.00 0.00 0.08 0.15

Curanex Pharmaceuticals Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.20 0.11 5.83 4.97
CURX
12GF Score
Curanex Pharmaceuticals Inc CURX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curanex Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $4.97 Mil mean?
Curanex Pharmaceuticals (CURX) has a Beginning Cash Position of $4.97 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Curanex Pharmaceuticals and its competitors.
Is Curanex Pharmaceuticals' Beginning Cash Position too high?
Curanex Pharmaceuticals' current Beginning Cash Position is $4.97 Mil. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' Beginning Cash Position compare to DRMA and NCNA?
Curanex Pharmaceuticals' Beginning Cash Position of $4.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Curanex Pharmaceuticals and its competitors. Curanex Pharmaceuticals's current Beginning Cash Position is $4.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current Beginning Cash Position of $4.97 Mil. The current Beginning Cash Position is $4.97 Mil. Curanex Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current Beginning Cash Position is $4.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curanex Pharmaceuticals Business Description

Address 2 Jericho Plaza, B Wing, Suite 101, Jericho, NY, USA, 11753
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score

Get the complete analysis for CURX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price